Press release
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted our clinical services for health claim trials as a response to new regulations by the European Parliamentary Committee on Environment, Public Health and Food Safety (ENVI). With this adjustment, we are now an expert provider of clinical services for manufacturers of dietary supplements and functional foods‘.
ICRC-Weyer has furthermore enhanced its medical data management services and introduced new medical coding procedures in 2012, enabling the CRO to deliver expert services by knowledgeable medical staff in the areas of manual medical data validation, medical coding as well as planning and organisation of ICRC-Weyer’s specialist medical review services.
‘One of the key adjustments in our services portfolio was the extension of our clinical monitoring services to monitoring for trials in the area of stem cell research’ Mr Weyer continues. ‘With this new feature we were able to establish new partnerships with pharmaceutical companies in the field of regenerative medicine’.
ICRC-Weyer participated in a number of industry events such as the 13th Euroforum Annual Conference on Nutrition, the AGAH Annual Meeting in Leipzig, the Evolution Summit in Munich as well as the EMWA Conference in Berlin. The company furthermore introduced a new communication strategy by starting to engage in discussions on the large social networks such as LinkedIn, Facebook and Google+ with industry professionals and people generally interested in clinical research. The company also grew in size, with new employees reinforcing the team in various clinical departments.
‘All in all, it was a very successful year, and we look forward to continuing this trend in 2013. We would like to thank all our employees for their hard work as well as our clients, partners and stakeholders.’
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process. ICRC-Weyer has special expertise in Advanced Therapies, Nutrition, CDISC Data Standards and Medical Review.
ICRC-Weyer GmbH
Boelschestrasse 2, 12587 Berlin, Germany
Phone: +49 30 403937-0
E-mail: daniel.weyer@icrc-weyer.com
www.icrc-weyer.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012 here
News-ID: 246692 • Views: …
More Releases from ICRC-Weyer GmbH
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors.
An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors.
‘A large…
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives…
More Releases for Weyer
Global Neonatal Incubator Market - AHT, Natus Medical, Weyer GmbH, Fanem
The report that is written on the title Neonatal Incubator Market covers all across the globe, recently added to the repository of Market Research, is titled ‘Global Neonatal Incubator Market 2017’. The research report analyses the historical as well as present performance of the worldwide Neonatal Incubator industry, and makes predictions on the future status of Neonatal Incubator market on the basis of this analysis.
An infant incubator is a…
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives…
Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in…
New Medical Coding Procedures At Clinical CRO ICRC-Weyer
ICRC-Weyer GmbH has announced an enhancement to their medical coding procedures for drug development processes.
Until recently, the company had been utilizing limited licenses for the coding dictionary of the World Health Organization WHO (WHO DD/WHO Drug). WHO DD is an international classification of medicines created by the WHO Programme for International Drug Monitoring and managed by the Uppsala Monitoring Centre. It is used by pharmaceutical companies, clinical trial organizations…
